Immunome (IMNM) AI Stock Analysis

• Market Cap: $1.57B
• Dividend Yield: N/A
• Average Volume (3M): 1.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: -4.44%
• EPS Growth: 63.58%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 91,710,270
• 10 Day Avg. Volume: 1,613,490
• 30 Day Avg. Volume: 1,383,084
• PEG Ratio: 0.30
• Price to Book (P/B): 3.44
• Price to Sales (P/S): 68.88
• P/FCF Ratio: -5.28
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 78.66
• Enterprise Value/Gross Profit: -18.92
• Enterprise Value/Ebitda: -3.78
• 1Y Price Target: $23.57
• Price Target Upside: 31.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -2.19
• Revenue Forecast (FY): $7.86M

• Rating: 56 Neutral
• Price Target: $18.00 ▲(0.78% Upside)

Immunome's stock score is primarily influenced by its challenging financial performance, with significant losses impacting profitability. However, the technical analysis indicates strong bullish momentum, which is a positive factor. The valuation is negatively impacted by the negative P/E ratio and lack of dividend yield.

Positive Factors

Revenue Growth

Consistent revenue growth indicates increasing market acceptance of Immunome's therapies, suggesting potential for long-term expansion and stability in the biotechnology sector.

Cash Flow Improvement

Improving cash generation capabilities enhance Immunome's ability to fund R&D and operational activities, supporting sustained business development and financial health.

Low Leverage

Minimal leverage reduces financial risk, providing Immunome with greater flexibility to invest in growth opportunities and navigate industry challenges without significant debt burden.

Negative Factors

Negative Profitability

Persistent losses impact Immunome's profitability, challenging its ability to achieve sustainable financial performance and potentially limiting reinvestment in growth initiatives.

Operational Inefficiencies

Operational inefficiencies reflected in negative margins may hinder Immunome's capacity to improve profitability, necessitating strategic adjustments to enhance operational effectiveness.

Negative Return on Equity

A negative return on equity indicates significant losses relative to shareholder equity, posing challenges for investor confidence and long-term shareholder value creation.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

How the Company Makes Money

Immunome generates revenue primarily through the development and commercialization of its therapeutic candidates, which are designed to address specific disease indications. The company may earn income through various streams, including milestone payments from partnerships with pharmaceutical companies, royalties from product sales once therapies are commercialized, and funding from grants or government contracts aimed at supporting research and development efforts. Significant collaborations with larger pharmaceutical companies can also provide upfront payments and additional funding tied to the achievement of development milestones, significantly contributing to the company's financial stability and growth.

Immunome Financial Statement Overview

Summary

Immunome faces significant financial challenges with negative profitability metrics, including a net profit margin of -16.87% and a negative return on equity of -87.36%. However, positive revenue growth of 15.09% and free cash flow growth of 15.20% suggest potential for improvement. The low debt-to-equity ratio indicates minimal financial risk.

Income Statement

Immunome's income statement shows a challenging financial position with a negative net profit margin of -16.87% TTM, indicating significant losses relative to revenue. However, there is a positive revenue growth rate of 15.09% TTM, suggesting potential for future improvement. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a low debt-to-equity ratio of 0.015 TTM, indicating minimal leverage and financial risk. However, the return on equity is negative at -87.36% TTM, highlighting significant losses relative to shareholder equity. The equity ratio is stable, suggesting a solid capital structure despite profitability challenges.

Cash Flow

Cash flow analysis shows a negative operating cash flow, but a free cash flow to net income ratio of 1.04 TTM suggests that cash flow is slightly better than net income. The free cash flow growth rate is positive at 15.20% TTM, indicating improving cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.68M	9.04M	14.02M	0.00	0.00	0.00
Gross Profit	-40.23M	9.04M	14.02M	0.00	0.00	-755.00K
EBITDA	-201.54M	-151.35M	-28.00M	-36.27M	-24.45M	-17.04M
Net Income	-222.74M	-292.96M	-106.81M	-36.90M	-24.71M	-17.84M
Balance Sheet
Total Assets	299.38M	240.24M	148.54M	24.05M	57.92M	44.52M
Cash, Cash Equivalents and Short-Term Investments	272.64M	217.30M	138.14M	20.32M	49.23M	39.77M
Total Debt	4.01M	4.83M	1.65M	291.00K	317.00K	613.00K
Total Liabilities	35.46M	59.08M	28.66M	7.39M	9.74M	3.18M
Stockholders Equity	263.92M	181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow
Free Cash Flow	-192.09M	-164.30M	-8.40M	-28.94M	-18.30M	-12.72M
Operating Cash Flow	-185.03M	-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
Investing Cash Flow	74.56M	-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
Financing Cash Flow	227.65M	240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 17.86 is above the 20-day moving average (MA) of 16.40, above the 50-day MA of 13.89, and above the 200-day MA of 10.24, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 62.61 is Neutral, neither overbought nor oversold. The STOCH value of 75.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMNM	56 Neutral	$1.57B	―	-93.04%	―	-4.44%	63.58%
IMTX	56 Neutral	$1.24B	―	-29.01%	―	-27.61%	-69.49%
TSHA	52 Neutral	$1.13B	―	-64.93%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNGX	48 Neutral	$1.10B	―	-51.65%	―	53.28%	21.77%
GERN	47 Neutral	$714.96M	―	-29.57%	―	522.13%	62.68%
SANA	33 Underperform	$1.06B	―	-96.11%	―	―	31.16%

Immunome Corporate Events

Immunome, Inc. Reports Q3 2025 Financial Results

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies aimed at improving outcomes for cancer patients. In its latest earnings report for the quarter ending September 30, 2025, Immunome highlighted a significant increase in cash and cash equivalents, reaching $272.6 million, compared to $143.4 million at the end of 2024. The company reported a net loss of $57.5 million for the quarter, reflecting increased research and development expenses as it advances its therapeutic candidates. Despite the absence of collaboration revenue this quarter, Immunome successfully raised $161.7 million through a public offering and $44.9 million via an ‘at the market’ sales agreement, bolstering its financial position. Looking forward, Immunome’s management remains focused on advancing its pipeline and anticipates that its current financial resources will support operations for at least the next 12 months, with plans to seek additional capital for long-term objectives.

Immunome’s Phase 1 Cancer Study: A Potential Game-Changer?

Immunome, Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies.’ The study aims to evaluate the safety and effectiveness of IM-1021, an antibody-drug conjugate, in treating individuals with advanced solid and hematologic cancers. This research is significant as it explores new treatment avenues for challenging cancer types.